Clinical trials of p-glycoprotein reversal in solid tumours

This publication has 82 references indexed in Scilit:

• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells
  European Journal of Pharmacology: Molecular Pharmacology, 1994
• Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells
  European Journal Of Cancer, 1993
• P-glycoprotein possesses A 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site
  Biochemical and Biophysical Research Communications, 1992
• Overexpression of the MDR1 Gene and P-Glycoprotein in Human Hepatocellular Carcinoma
  JNCI Journal of the National Cancer Institute, 1992
• Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo
  European Journal Of Cancer, 1992
• Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A
  European Journal of Cancer and Clinical Oncology, 1991
• Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients
  European Journal of Cancer and Clinical Oncology, 1991
• (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of α1-adrenoceptors
  European Journal of Pharmacology: Molecular Pharmacology, 1989
• A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
  British Journal of Cancer, 1971